The study began on May 20, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025, indicating the study is actively ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.. The ...

The rival drug has been shown to help extend lives, opens new tab of NSCLC patients by 38.6 months on average in a separate study. AstraZeneca did not immediately respond to a request for comment.

NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart Failure and Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).

AstraZeneca has declined to announce a price for camizestrant if it receives government approval. But a similar drug, elacestrant, made by Stemline Therapeutics, typically costs $26,467.56 a month.